MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
debt
$350,000K
Sales and maturities
of marketable...
$1,083,297K
Proceeds from issuance or
sale of...
$38,055K
Net cash provided by
financing activities
$255,984K
Net cash provided by
(used in) investing...
$32,320K
Effect of exchange rate
changes on cash, cash...
$13K
Canceled cashflow
$132,071K
Canceled cashflow
$1,050,977K
Net increase
(decrease) in cash, cash...
$98,764K
Canceled cashflow
$189,553K
Repayment of debt
$121,664K
Payment of debt issuance
costs
$10,407K
Accrued liabilities
$131,902K
Stock-based compensation
expense
$98,130K
Accrued interest, net of
interest received on...
$5,971K
Accounts payable
$5,279K
Amortization and interest
accretion related to...
$3,210K
Loss on
extinguishment of debt
-$2,779K
Amortization of debt issuance
costs and discount
$1,604K
Depreciation and
amortization expense
$1,506K
Purchases of marketable
securities
$1,047,510K
Acquisition of intangible
asset
$3,000K
Purchases of property and
equipment, net of disposals
$467K
Net cash used in
operating activities
-$189,553K
Canceled cashflow
$250,381K
Net loss
-$288,284K
Trade receivables,
net
$80,654K
Inventory
$36,978K
Prepaid expenses and
other current assets
$34,018K
Back
Back
Cash Flow
source: myfinsight.com
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)